Procainamide in the dog: antiarrhythmic plasma concentrations after intravenous administration.
Procainamide hydrochloride was administered to ouabain-intoxicated dogs to determine an antiarrhythmic plasma concentration of procainamide. Ventricular arrhythmias were produced in dogs following intravenous injections of ouabain. After a sustained ventricular tachycardia was achieved, procainamide was administered and plasma samples collected for assay. Plasma procainamide was assayed by fluorescence polarization immunoassay. Procainamide was administered at increasingly higher constant rate infusions in order to achieve intermittent, steady-state plasma concentrations. Infusion rates were calculated on the basis of previous pharmacokinetic information. All six dogs that received procainamide converted to a normal sinus cardiac rhythm after attaining a mean plasma concentration of 33.8 micrograms/ml with a range of 48.5 micrograms/ml-25.0 micrograms/ml. It was observed that the computer-generated prediction of plasma concentrations based upon previous pharmacokinetic data produced an underestimate of the actual plasma concentrations. These data may suggest that plasma concentrations of procainamide for controlling some cardiac arrhythmias in dogs may be higher than plasma concentrations cited for human patients.
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy / Q000662:veterinary*; D003198:Computer Simulation; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004562:Electrocardiography; D005260:Female; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D010042:Ouabain; D011342:Procainamide / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*
D010042:Ouabain; D011342:Procainamide